Cepheid Xpert MTB/RIF

Xpert MTB/RIF is an advanced, cartridge-based nucleic acid amplification test (NAAT) designed for the rapid detection of Mycobacterium tuberculosis complex (MTBC) DNA and rifampicin (RIF) resistance. This assay delivers results in under two hours, significantly accelerating the diagnosis of tuberculosis (TB) and the identification of multidrug-resistant strains.

Key features include:

• Rapid turnaround: Provides results in less than two hours, enabling prompt clinical decisions.
• High sensitivity and specificity: Demonstrates a sensitivity of 89% and specificity of 99% when used as an initial diagnostic test.
• Automated process: Utilises the GeneXpert® System for fully automated sample processing and real-time PCR analysis.
• Minimal technical training required: Designed for ease of use, allowing deployment in diverse healthcare settings.

This diagnostic tool is widely applied in:

• Clinical microbiology: For the detection and management of TB infections.
• Infectious disease research: Facilitating studies on TB epidemiology and drug resistance patterns.
• Public health initiatives: Supporting TB control programmes by enabling rapid case detection and treatment initiation.

Commonly utilised in:

• Hospitals and clinics: For on-site, rapid TB testing and immediate treatment decisions.
• Public health laboratories: Enhancing surveillance and monitoring of TB prevalence and resistance.
• Research institutions: Conducting studies on TB diagnostics and treatment efficacy.

First endorsed by the World Health Organization (WHO) in 2010, the Xpert MTB/RIF assay has been instrumental in revolutionising TB diagnostics, particularly in resource-limited settings. Its rapid and accurate detection capabilities have made it a cornerstone in the global fight against tuberculosis.